Calidi Biotherapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $-19.9M | $-22.1M | $-29.2M | $-25.4M |
| Depreciation & Amortization | $1.7M | $1.5M | — | — |
| Depreciation | — | $402.0K | $392.0K | $260.0K |
| Amortization | — | — | — | — |
| Stock-Based Compensation | $2.1M | $3.0M | $4.8M | $4.5M |
| Net Cash from Operating Activities | $-21.3M | $-19.7M | $-27.0M | $-13.2M |
| Investing Activities | ||||
| Capital Expenditures | — | — | — | — |
| Business Acquisitions | — | — | — | — |
| Net Cash from Investing Activities | $-170.0K | $-16.0K | $-478.0K | $-494.0K |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | — | — | — | — |
| Net Cash from Financing Activities | $17.5M | $27.4M | $29.0M | $12.1M |
| Net Change in Cash | $-4.0M | $7.6M | $1.6M | $-968.8K |
| Free Cash Flow | — | — | — | — |